Treatment of homozygous familial hypercholesterolemia

References

• Stein EA, Honarpour N, Wasserman SM, Xu F, Scott R, Raal FJ. Effect of the PCSK9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia.Circulation 128(19), 2113–2120 (2013). ▪▪ Trial evidence for the effectiveness of PCSK9 inhibition in homozygous familial hypercholesterolemia.
   Google Scholar
• Raal FJ, Pilcher GJ, Panz VR et al. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid‑lowering therapy.Circulation 124(20), 2202–2207 (2011). ▪▪ Good review of recent therapeutic developments for lipid disorders.
   Google Scholar
• Raal F, Panz V, Immelman A, Pilcher G. Elevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to high‑dose statin therapy. J. Am. Heart Assoc. 2(2), e000028 (2013).
   Google Scholar
• Bertolini S, Cantafora A, Averna M et al. Clinical expression of familial hypercholesterolemia in clusters of mutations of the LDL receptor gene that cause a receptordefective or receptor‑negative phenotype.Arterioscler. Thromb. Vasc. Biol. 20(9), E41–E52 (2000).
   Google Scholar
• Dedoussis GV, Skoumas J, Pitsavos C et al. FH clinical phenotype in Greek patients with LDL‑R defective vs. negative mutations. Eur. J. Clin. Invest. 34(6), 402–409 (2004).
   Google Scholar
• Bertolini S, Cassanelli S, Garuti R et al. Analysis of LDL receptor gene mutations in Italian patients with homozygous familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 19(2), 408–418 (1999).
   Google Scholar
• Abifadel M, Varret M, Rabes JP et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34(2), 154–156 (2003).
   Google Scholar
• Innerarity TL, Weisgraber KH, Arnold KS et al. Familial defective apolipoprotein B‑100: low density lipoproteins with abnormal receptor binding. Proc. Natl Acad. Sci. USA 84(19), 6919–6923 (1987).
   Google Scholar
• Myant NB, Gallagher JJ, Knight BL et al. Clinical signs of familial hypercholesterolemia in patients with familial defective apolipoprotein B‑100 and normal low density lipoprotein receptor function. Arterioscler. Thromb. 11(3), 691–703 (1991).
   Google Scholar
• Garcia CK, Wilund K, Arca M et al. Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. Science 292(5520), 1394–1398 (2001).
   Google Scholar
• Pisciotta L, Priore Oliva C, Pes GM et al. Autosomal recessive hypercholesterolemia (ARH) and homozygous familial hypercholesterolemia (FH): a phenotypic comparison. Atherosclerosis 188(2), 398–405 (2006).
   Google Scholar
• Soutar AK, Naoumova RP, Traub LM. Genetics, clinical phenotype, and molecular cell biology of autosomal recessive hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 23(11), 1963–1970 (2003).
   Google Scholar
• Hovingh GK, Davidson MH, Kastelein JJ, O’Connor AM. Diagnosis and treatment of familial hypercholesterolaemia. Eur. Heart J. 34(13), 962–971 (2013).
   Google Scholar
• Uauy R, Zwiener RJ, Phillips MJ, Petruska ML, Bilheimer DW. Treatment of children with homozygous familial hypercholesterolemia: safety and efficacy of low‑density lipoprotein apheresis. J. Pediatr. 120(6), 892–898 (1992).
   Google Scholar
• Kolansky DM, Cuchel M, Clark BJ et al. Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia.Am. J. Cardiol. 102(11), 1438–1443 (2008).
   Google Scholar
• Rallidis L, Naoumova RP, Thompson GR, Nihoyannopoulos P. Extent and severity of atherosclerotic involvement of the aortic valve and root in familial hypercholesterolaemia.Heart 80(6), 583–590 (1998). ▪ Clinical review of the important topic of aortic valve and supravalvular disease in hypercholesterolemia.
   Google Scholar
• Walzer S, Travers K, Rieder S, Erazo‑Fischer E, Matusiewicz D. Homozygous familial hypercholesterolemia (HoFH) in Germany: an epidemiological survey. Clinicoecon. Outcomes Res. 5, 189–192 (2013).
   Google Scholar
• Raal FJ, Santos RD. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis 223(2), 262–268 (2012).
   Google Scholar
• Austin MA, Zimmern RL, Humphries SE. High ‘population attributable fraction’ for coronary heart disease mortality among relatives in monogenic familial hypercholesterolemia. Genet. Med. 4(4), 275–278 (2002).
   Google Scholar
• Filigheddu F, Quagliarini F, Campagna F et al. Prevalence and clinical features of heterozygous carriers of autosomal recessive hypercholesterolemia in Sardinia.Atherosclerosis 207(1), 162–167 (2009).
   Google Scholar
• Sun XM, Patel DD, Knight BL, Soutar AK. Influence of genotype at the low density lipoprotein (LDL) receptor gene locus on the clinical phenotype and response to lipidlowering drug therapy in heterozygous familial hypercholesterolaemia. The Familial Hypercholesterolaemia Regression Study Group. Atherosclerosis 136(1), 175–185 (1998).
   Google Scholar
• Jeenah M, September W, Graadt van Roggen F, de Villiers W, Seftel H, Marais D. Influence of specific mutations at the LDLreceptor gene locus on the response to simvastatin therapy in Afrikaner patients with heterozygous familial hypercholesterolaemia.Atherosclerosis 98(1), 51–58 (1993).
   Google Scholar
• Zelcer N, Hong C, Boyadjian R, Tontonoz P. LXR regulates cholesterol uptake through Idol‑dependent ubiquitination of the LDL receptor. Science 325(5936), 100–104 (2009).
   Google Scholar
• Sawamura T. New Idol for cholesterol reduction? Clin. Chem. 55(12), 2082–2084 (2009).
   Google Scholar
• Ikonen E. Cellular cholesterol trafficking and compartmentalization. Nat. Rev. Mol. Cell Biol. 9(2), 125–138 (2008).
   Google Scholar
• Goldstein JL, Debose‑Boyd RA, Brown MS. Protein sensors for membrane sterols. Cell 124(1), 35–46 (2006). ▪▪ Comprehensive review of cholesterol metabolism.
   Google Scholar
• Soufi M, Ruppert V, Kurt B, Schaefer JR. The impact of severe LDL receptor mutations on SREBP‑pathway regulation in homozygous familial hypercholesterolemia (FH). Gene 499(1), 218–222 (2012).
   Google Scholar
• Goldberg RB, Fless GM, Baker SG et al. Abnormalities of high density lipoproteins in homozygous familial hypercholesterolemia.Arteriosclerosis 4(5), 472–478 (1984).
   Google Scholar
• Hussain MM, Rava P, Walsh M, Rana M, Iqbal J. Multiple functions of microsomal triglyceride transfer protein. Nutr. Metab. (Lond.) 9, 14 (2012).
   Google Scholar
• Haas ME, Attie AD, Biddinger SB. The regulation of ApoB metabolism by insulin.Trends Endocrinol. Metab. 24(8), 391–397 (2013).
   Google Scholar
• Larsson SL, Skogsberg J, Bjorkegren J. The low density lipoprotein receptor prevents secretion of dense apoB100‑containing lipoproteins from the liver. J. Biol. Chem. 279(2), 831–836 (2004).
   Google Scholar
• Sniderman AD, De Graaf J, Couture P, Williams K, Kiss RS, Watts GF. Regulation of plasma LDL: the apoB paradigm. Clin. Sci. (Lond.) 118(5), 333–339 (2010). ▪ Review of the significance of increased apoB-containing LP turnover.
   Google Scholar
• Ouguerram K, Chetiveaux M, Zair Y et al. Apolipoprotein B100 metabolism in autosomal‑dominant hypercholesterolemia related to mutations in PCSK9. Arterioscler. Thromb. Vasc. Biol. 24(8), 1448–1453 (2004).
   Google Scholar
• Zulewski H, Ninnis R, Miserez AR, Baumstark MW, Keller U. VLDL and IDL apolipoprotein B‑100 kinetics in familial hypercholesterolemia due to impaired LDL receptor function or to defective apolipoprotein B‑100. J. Lipid Res. 39(2), 380–387 (1998).
   Google Scholar
• Jones C, Hammer RE, Li WP, Cohen JC, Hobbs HH, Herz J. Normal sorting but defective endocytosis of the low density lipoprotein receptor in mice with autosomal recessive hypercholesterolemia. J. Biol. Chem. 278(31), 29024–29030 (2003).
   Google Scholar
• Kraft HG, Lingenhel A, Raal FJ, Hohenegger M, Utermann G. Lipoprotein(a) in homozygous familial hypercholesterolemia.Arterioscler. Thromb. Vasc. Biol. 20(2), 522–528 (2000).
   Google Scholar
• Dikkers A, Tietge UJ. Biliary cholesterol secretion: more than a simple ABC. World J. Gastroenterol. 16(47), 5936–5945 (2010). ▪▪ Comprehensive review of biliary cholesterol excretion.
   Google Scholar
• Schwarz KB, Witztum J, Schonfeld G, Grundy SM, Connor WE. Elevated cholesterol and bile acid synthesis in a young patient with homozygous familial hypercholesterolemia. J. Clin. Invest. 64(3), 756–760 (1979).
   Google Scholar
• Le May C, Berger JM, Lespine A et al. Transintestinal cholesterol excretion is an active metabolic process modulated by PCSK9 and statin involving ABCB1.Arterioscler. Thromb. Vasc. Biol. 33(7), 1484–1493 (2013).
   Google Scholar
• Descamps OS, Tenoutasse S, Stephenne X et al. Management of familial hypercholesterolemia in children and young adults: consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patient organization.Atherosclerosis 218(2), 272–280 (2011).
   Google Scholar
• Ito MK, McGowan MP, Moriarty PM. Management of familial hypercholesterolemias in adult patients: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J. Clin. Lipidol. 5(Suppl. 3), S38–S45 (2011).
   Google Scholar
• Reiner Z, Catapano AL, De Backer G et al. ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).Eur. Heart J. 32(14), 1769–1818 (2011).
   Google Scholar
• Thompson GR, Catapano A, Saheb S et al. Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe. Curr. Opin. Lipidol. 21(6), 492–498 (2010).
   Google Scholar
• Bambauer R, Bambauer C, Lehmann B, Latza R, Schiel R. LDL‑apheresis: technical and clinical aspects. ScientificWorldJournal 2012, 314283 (2012). ▪▪ Comprehensive review of LDL apheresis.
   Google Scholar
• Spady DK, Bilheimer DW, Dietschy JM. Rates of receptor‑dependent and ‑independent low density lipoprotein uptake in the hamster.Proc. Natl Acad. Sci. USA 80(11), 3499–3503 (1983).
   Google Scholar
• Thompson GR, Ford J, Jenkinson M, Trayner I. Efficacy of mevinolin as adjuvant therapy for refractory familial hypercholesterolaemia.Q. J. Med. 60(232), 803–811 (1986).
   Google Scholar
• Bilheimer DW, Grundy SM, Brown MS, Goldstein JL. Mevinolin and colestipol stimulate receptor‑mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc. Natl Acad. Sci. USA 80(13), 4124–4128 (1983).
   Google Scholar
• de Gennes JL, Touraine R, Maunand B, Truffert J, Laudat P. [Homozygous cutaneotendinous forms of hypercholesteremic xanthomatosis in an exemplary familial case. Trial of plasmapheresis ans heroic treatment].Bull. Mem. Soc. Med. Hop. Paris 118(15), 1377–1402 (1967).
   Google Scholar
• Thompson GR, Lowenthal R, Myant NB. Plasma exchange in the management of homozygous familial hypercholesterolaemia.Lancet 1(7918), 1208–1211 (1975).
   Google Scholar
• Klingel R, Mausfeld P, Fassbender C, Goehlen B. Lipidfiltration – safe and effective methodology to perform lipid‑apheresis.Transfus. Apher. Sci. 30(3), 245–254 (2004).
   Google Scholar
• Koll RA. LDL‑Therasorb immunoadsorption for the treatment of severe hypercholesterolemia refractory to conventional therapy. Ther. Apher. 2(2), 142–146 (1998).
   Google Scholar
• Bosch T. Practical aspects of direct adsorption of lipoproteins from whole blood by DALI LDL‑apheresis. Transfus. Apher. Sci. 31(2), 83–88 (2004).
   Google Scholar
• Bosch T, Wendler T. Efficacy and safety of DALI–LDL‑apheresis in two patients treated with the angiotensin II‑receptor 1 antagonist losartan. Ther. Apher. Dial. 8(4), 269–274 (2004).
   Google Scholar
• Hequet O, Le QH, Rigal D et al. The first results demonstrating efficiency and safety of a double‑column whole blood method of LDL‑apheresis. Transfus. Apher. Sci. 42(1), 3–10 (2010).
   Google Scholar
• Stefanutti C, Julius U. Lipoprotein apheresis: state of the art and novelties. Atheroscler. Suppl. 14(1), 19–27 (2013). ▪ Review of the interplay between lipid-lowering drug treatment and LDL apheresis.
   Google Scholar
• Otto C, Berster J, Otto B, Parhofer KG. Effects of two whole blood systems (DALI and Liposorber D) for LDL apheresis on lipids and cardiovascular risk markers in severe hypercholesterolemia. J. Clin. Apher. 22(6), 301–305 (2007).
   Google Scholar
• Schmaldienst S, Banyai S, Stulnig TM et al. Prospective randomised cross‑over comparison of three LDL‑apheresis systems in statin pretreated patients with familial hypercholesterolaemia. Atherosclerosis 151(2), 493–499 (2000).
   Google Scholar
• Stefanutti C, Di Giacomo S, Mazzarella B, Castelli A. LDL apheresis: a novel technique (LIPOCOLLECT 200). Artif. Organs 33(12), 1103–1108 (2009).
   Google Scholar
• Neumann CL, Schulz EG, Hagenah GC, Platzer U, Wieland E, Schettler V. Lipoprotein apheresis – more than just cholesterol reduction? Atheroscler. Suppl. 14(1), 29–32 (2013).
   Google Scholar
• Ramunni A, Burzo M, Verno L, Brescia P. Pleiotropic effects of LDL apheresis. Atheroscler. Suppl. 10(5), 53–55 (2009).
   Google Scholar
• Lepage S, Nigon F, Bonnefont‑Rousselot D et al. Oxidizability of atherogenic low‑density lipoprotein subspecies in severe familial hypercholesterolemia: impact of long‑term low‑density lipoprotein apheresis.J. Cardiovasc. Pharmacol. Ther. 5(2), 87–103 (2000).
   Google Scholar
• Borberg H. 26 years of LDL – apheresis: a review of experience. Transfus. Apher. Sci. 41(1), 49–59 (2009).
   Google Scholar
• Koga N, Nagano T, Sato T, Kagasawa K. Anaphylactoid reactions and bradykinin generation in patients treated with LDLapheresis and an ACE inhibitor. ASAIO J. 39(3), M288–M291 (1993).
   Google Scholar
• Kojima S, Ogi M, Yoshitomi Y et al. Changes in bradykinin and prostaglandins plasma levels during dextran‑sulfate low‑density‑lipoprotein apheresis. Int. J. Artif. Organs 20(3), 178–183 (1997).
   Google Scholar
• Julius U, Tselmin S, Fischer S, Passauer J, Bornstein SR. The Dresden Apheresis Center – experience with LDL apheresis and immunoadsorption. Atheroscler. Suppl. 10(5), 12–16 (2009).
   Google Scholar
• Keller C. LDL‑apheresis in homozygous LDL‑receptor‑defective familial hypercholesterolemia: the Munich experience.Atheroscler. Suppl. 10(5), 21–26 (2009).
   Google Scholar
• Graesdal A, Bogsrud MP, Holven KB et al. Apheresis in homozygous familial hypercholesterolemia: the results of a followup of all Norwegian patients with homozygous familial hypercholesterolemia.J. Clin. Lipidol. 6(4), 331–339 (2012).
   Google Scholar
• Hudgins LC, Kleinman B, Scheuer A, White S, Gordon BR. Long‑term safety and efficacy of low‑density lipoprotein apheresis in childhood for homozygous familial hypercholesterolemia. Am. J. Cardiol. 102(9), 1199–1204 (2008).
   Google Scholar
• Thompson GR, Miller JP, Breslow JL. Improved survival of patients with homozygous familial hypercholesterolaemia treated with plasma exchange. Br. Med. J. (Clin. Res. Ed.) 291(6510), 1671–1673 (1985).
   Google Scholar
• Kroon AA, Aengevaeren WR, van der Werf T et al. LDL‑Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis.Circulation 93(10), 1826–1835 (1996).
   Google Scholar
• Matsuzaki M, Hiramori K, Imaizumi T et al. Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein‑apheresis in familial hypercholesterolemia: the Low Density Lipoprotein‑Apheresis Coronary Morphology and Reserve Trial (LACMART). J. Am. Coll. Cardiol. 40(2), 220–227 (2002).
   Google Scholar
• Guardamagna O, Cagliero P, Abello F. Management of inherited atherogenic dyslipidemias in children. Ther. Apher. Dial. 17(2), 150–161 (2013).
   Google Scholar
• Palcoux JB, Atassi‑Dumont M, Lefevre P et al. Low‑density lipoprotein apheresis in children with familial hypercholesterolemia: follow‑up to 21 years. Ther. Apher. Dial. 12(3), 195–201 (2008).
   Google Scholar
• Dann EJ, Shamir R, Mashiach T et al. Earlyonset plasmapheresis and LDL‑apheresis provide better disease control for pediatric homozygous familial hypercholesterolemia than HMG‑CoA reductase inhibitors and ameliorate atherosclerosis. Transfus. Apher. Sci. 49(2), 268–277 (2013).
   Google Scholar
• Ertorer ME, Guvenc B, Haydardedeoglu B, Tekinturhan F. A case report of the cascade filtration system: a safe and effective method for low‑density lipoprotein apheresis during pregnancy. Ther. Apher. Dial. 12(5), 396–400 (2008).
   Google Scholar
• Teruel JL, Lasuncion MA, Navarro JF, Carrero P, Ortuno J. Pregnancy in a patient with homozygous familial hypercholesterolemia undergoing low‑density lipoprotein apheresis by dextran sulfate adsorption. Metabolism 44(7), 929–933 (1995).
   Google Scholar
• Kroon AA, Swinkels DW, van Dongen PW, Stalenhoef AF. Pregnancy in a patient with homozygous familial hypercholesterolemia treated with long‑term low‑density lipoprotein apheresis. Metabolism 43(9), 1164–1170 (1994).
   Google Scholar
• Mihaylova B, Emberson J, Blackwell L et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta‑analysis of individual data from 27 randomised trials. Lancet 380(9841), 581–590 (2012).
   Google Scholar
• Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Scientific Steering Committee on behalf of the Simon Broome Register Group. Atherosclerosis 142(1), 105–112 (1999).
   Google Scholar
• Versmissen J, Oosterveer DM, Yazdanpanah M et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ 337, a2423 (2008).
   Google Scholar
• Stary HC, Chandler AB, Glagov S et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 89(5), 2462–2478 (1994).
   Google Scholar
• Arambepola C, Farmer AJ, Perera R, Neil HA. Statin treatment for children and adolescents with heterozygous familial hypercholesterolaemia: a systematic review and meta‑analysis. Atherosclerosis 195(2), 339–347 (2007).
   Google Scholar
• Vuorio A, Kuoppala J, Kovanen PT et al. Statins for children with familial hypercholesterolemia. Cochrane Database Syst. Rev. 7, CD006401 (2010).
   Google Scholar
• Yamamoto A, Sudo H, Endo A. Therapeutic effects of ML‑236B in primary hypercholesterolemia. Atherosclerosis 35(3), 259–266 (1980).
   Google Scholar
• Marais AD, Blom DJ, Firth JC. Statins in homozygous familial hypercholesterolemia.Curr. Atheroscler. Rep. 4(1), 19–25 (2002).
   Google Scholar
• Raal FJ, Pilcher GJ, Illingworth DR et al. Expanded‑dose simvastatin is effective in homozygous familial hypercholesterolaemia.Atherosclerosis 135(2), 249–256 (1997).
   Google Scholar
• Raal FJ, Pappu AS, Illingworth DR et al. Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia. Atherosclerosis 150(2), 421–428 (2000).
   Google Scholar
• Marais AD, Raal FJ, Stein EA et al. A dosetitration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia.Atherosclerosis 197(1), 400–406 (2008).
   Google Scholar
• Marais AD, Naoumova RP, Firth JC, Penny C, Neuwirth CK, Thompson GR. Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia. J. Lipid Res. 38(10), 2071–2078 (1997).
   Google Scholar
• Marais AD, Wood L, Firth JC, Hall JM, Jacobs P. Plasma exchange for homozygous familial hypercholesterolaemia: the Cape Town experience. Transfus. Sci. 14(3), 239–247 (1993).
   Google Scholar
• Rodenburg J, Vissers MN, Wiegman A et al. Statin treatment in children with familial hypercholesterolemia: the younger, the better.Circulation 116(6), 664–668 (2007).
   Google Scholar
• Vergeer M, Zhou R, Bots ML et al. Carotid atherosclerosis progression in familial hypercholesterolemia patients: a pooled analysis of the ASAP, ENHANCE, RADIANCE 1, and CAPTIVATE studies. Circ. Cardiovasc. Imaging 3(4), 398–404 (2010).
   Google Scholar
• Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double‑blind trial.Lancet 357(9256), 577–581 (2001).
   Google Scholar
• Stroes ES, Koomans HA, de Bruin TW, Rabelink TJ. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid‑lowering medication. Lancet 346(8973), 467–471 (1995).
   Google Scholar
• Ullrich H, Matic BG, Lackner KJ, Rothe G, Schmitz G. [Specific Lp(a) apheresis for secondary prevention of arteriosclerosis].Beitr. Infusionsther. Transfusionsmed. 34, 248–255 (1997).
   Google Scholar
• de Jongh S, Lilien MR, op’t Roodt J, Stroes ES, Bakker HD, Kastelein JJ. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J. Am. Coll. Cardiol. 40(12), 2117–2121 (2002).
   Google Scholar
• Gagne C, Gaudet D, Bruckert E. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia.Circulation 105(21), 2469–2475 (2002).
   Google Scholar
• Yamamoto A, Harada‑Shiba M, Endo M et al. The effect of ezetimibe on serum lipids and lipoproteins in patients with homozygous familial hypercholesterolemia undergoing LDL‑apheresis therapy. Atherosclerosis 186(1), 126–131 (2006).
   Google Scholar
• Davidson MH. A systematic review of bile acid sequestrant therapy in children with familial hypercholesterolemia. J. Clin. Lipidol. 5(2), 76–81 (2011).
   Google Scholar
• Davidson MH, Donovan JM, Misir S, Jones MR. A 50‑week extension study on the safety and efficacy of colesevelam in adults with primary hypercholesterolemia. Am. J. Cardiovasc. Drugs 10(5), 305–314 (2010).
   Google Scholar
• Costet P. Molecular pathways and agents for lowering LDL‑cholesterol in addition to statins. Pharmacol. Ther. 126(3), 263–278 (2010).
   Google Scholar
• Bell DA, Hooper AJ, Burnett JR. Mipomersen, an antisense apolipoprotein B synthesis inhibitor. Expert Opin. Investig. Drugs 20(2), 265–272 (2011).
   Google Scholar
• Kling J. Safety signal dampens reception for mipomersen antisense. Nat. Biotechnol. 28(4), 295–297 (2010).
   Google Scholar
• Hovingh K, Besseling J, Kastelein J. Efficacy and safety of mipomersen sodium (Kynamro).Expert Opin. Drug Saf. 12(4), 569–579 (2013).
   Google Scholar
• Kastelein JJ, Wedel MK, Baker BF et al. Potent reduction of apolipoprotein B and low‑density lipoprotein cholesterol by shortterm administration of an antisense inhibitor of apolipoprotein B. Circulation 114(16), 1729–1735 (2006).
   Google Scholar
• Akdim F, Visser ME, Tribble DL et al. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low‑density lipoprotein cholesterol in patients with familial hypercholesterolemia. Am. J. Cardiol. 105(10), 1413–1419 (2010).
   Google Scholar
• Akdim F, Stroes ES, Sijbrands EJ et al. Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy. J. Am. Coll. Cardiol. 55(15), 1611–1618 (2010).
   Google Scholar
• Parhofer KG. Mipomersen: evidence‑based review of its potential in the treatment of homozygous and severe heterozygous familial hypercholesterolemia. Core Evid. 7, 29–38 (2012).
   Google Scholar
• Raal FJ, Santos RD, Blom DJ et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double‑blind, placebo‑controlled trial. Lancet 375(9719), 998–1006 (2010).
   Google Scholar
• Durrington PN, Charlton‑Menys V, Packard CJ et al. Familial hypobetalipoproteinemia due to a novel early stop mutation. J. Clin. Lipidol. 2(5), 384–390 (2008).
   Google Scholar
• Perry CM. Lomitapide: a review of its use in adults with homozygous familial hypercholesterolemia. Am. J. Cardiovasc. Drugs 13(4), 285–296 (2013).
   Google Scholar
• Cuchel M, Meagher EA, du Toit Theron H et al.; Phase 3 HoFH Lomitapide Study investigators. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single‑arm, open‑label, Phase 3 study. Lancet 381(9860), 40–46 (2013). ▪ Recent trial evidence on the effectiveness of lomitapide.
   Google Scholar
• Raal FJ. Lomitapide for homozygous familial hypercholesterolaemia. Lancet 381(9860), 7–8 (2013).
   Google Scholar
• Stein EA, Dufour R, Gagne C et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double‑blind, placebo‑controlled trial to assess efficacy and safety as add‑on therapy in patients with coronary artery disease.Circulation 126(19), 2283–2292 (2012). ▪ Recent trial evidence on the effectiveness of mipomersen.
   Google Scholar
• Shen L, Peng H, Xu D, Zhao S. The next generation of novel low‑density lipoprotein cholesterol‑lowering agents: proprotein convertase subtilisin/kexin 9 inhibitors.Pharmacol. Res. 73, 27–34 (2013). ▪ Insight into the development of novel lipid-lowering drugs.
   Google Scholar
• Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354(12), 1264–1272 (2006).
   Google Scholar
• Benn M, Nordestgaard BG, Grande P, Schnohr P, Tybjaerg‑Hansen A. PCSK9 R46L, low‑density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta‑analyses. J. Am. Coll. Cardiol. 55(25), 2833–2842 (2010).
   Google Scholar
• Stein EA, Gipe D, Bergeron J et al. Effect of a monoclonal antibody to PCSK9, REGN727/ SAR236553, to reduce low‑density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a Phase 2 randomised controlled trial. Lancet 380(9836), 29–36 (2012).
   Google Scholar
• Raal F, Scott R, Somaratne R et al. Lowdensity lipoprotein cholesterol‑lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL‑C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.Circulation 126(20), 2408–2417 (2012).
   Google Scholar
• Li D, Weng S, Yang B et al. Inhibition of arterial thrombus formation by ApoA1 Milano. Arterioscler. Thromb. Vasc. Biol. 19(2), 378–383 (1999).
   Google Scholar
• McNeill E. RVX‑208, a stimulator of apolipoprotein AI gene expression for the treatment of cardiovascular diseases. Curr. Opin. Investig. Drugs 11(3), 357–364 (2010).
   Google Scholar
• Hewing B, Fisher EA. Rationale for cholesteryl ester transfer protein inhibition.Curr. Opin. Lipidol. 23(4), 372–376 (2012).
   Google Scholar
• Schofield JD, France M, Ammori B, Liu Y, Soran H. High‑density lipoprotein cholesterol raising: does it matter? Curr. Opin. Cardiol. 28(4), 464–474 (2013).
   Google Scholar
• Raal FM, Gagne AD, Gaudet C et al. Torcetrapib/Atorvastatin substantially raises HDL‑C and markedly lowers LDL‑C in patients with homozygous familial hypercholesterolemia. Atheroscler. Suppl. 8(1), 204 (2007).
   Google Scholar
• Raal FJ, Marais AD, Klepack E, Lovalvo J, McLain R, Heinonen T. Avasimibe, an ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia. Atherosclerosis 171(2), 273–279 (2003).
   Google Scholar
• Schwartz GG, Olsson AG, Ballantyne CM et al. Rationale and design of the dal‑OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am. Heart J. 158(6), 896–901 e893 (2009).
   Google Scholar
• Gotto AM Jr, Moon JE. Safety of inhibition of cholesteryl ester transfer protein with anacetrapib: the DEFINE study. Expert Rev. Cardiovasc. Ther. 10(8), 955–963 (2012).
   Google Scholar
• Grossman M, Rader DJ, Muller DW et al. A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia.Nat. Med. 1(11), 1148–1154 (1995).
   Google Scholar
• Grossman M, Raper SE, Kozarsky K et al. Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia. Nat. Genet. 6(4), 335–341 (1994).
   Google Scholar
• Al‑Allaf FA, Coutelle C, Waddington SN, David AL, Harbottle R, Themis M. LDLR‑gene therapy for familial hypercholesterolaemia: problems, progress, and perspectives. Int. Arch. Med. 3, 36 (2010).
   Google Scholar
• Thompson GR. Recommendations for the use of LDL apheresis. Atherosclerosis 198(2), 247–255 (2008).
   Google Scholar
• Thompson GR, Barbir M, Davies D et al. Efficacy criteria and cholesterol targets for LDL apheresis. Atherosclerosis 208(2), 317–321 (2010).
   Google Scholar
• Schettler V, Wieland E, Armstrong VW, Kleinoeder T, Grunewald RW, Muller GA. First steps toward the establishment of a German low‑density lipoprotein‑apheresis registry: recommendations for the indication and for quality management. Ther. Apher. 6(5), 381–383 (2002).
   Google Scholar
• Szczepiorkowski ZM, Bandarenko N, Kim HC et al. Guidelines on the use of therapeutic apheresis in clinical practice: evidence‑based approach from the Apheresis Applications Committee of the American Society for Apheresis. J. Clin. Apher. 22(3), 106–175 (2007).
   Google Scholar
• Schettler V, Neumann CL, Hagenah GC, Schulz EG, Wieland E. How to optimize lipoprotein apheresis treatment – a second look. Atheroscler. Suppl. 14(1), 89–92 (2013).
   Google Scholar
• Nordestgaard BG, Chapman MJ, Ray K et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur. Heart J. 31(23), 2844–2853 (2010).
   Google Scholar
• Joshi PH, Krivitsky E, Qian Z, Vazquez G, Voros S, Miller J. Do we know when and how to lower lipoprotein(a)? Curr. Treat. Options Cardiovasc. Med. 12(4), 396–407 (2010).
   Google Scholar
• Melnikova I. Rare diseases and orphan drugs. Nat. Rev. Drug Discov. 11(4), 267–268 (2012). ▪ Overview of drug development in rare diseases.
   Google Scholar
• Charlton‑Menys V, Durrington PN. Squalene synthase inhibitors: clinical pharmacology and cholesterol‑lowering potential. Drugs 67(1), 11–16 (2007).
   Google Scholar
• Stein EA, Bays H, O’Brien D, Pedicano J, Piper E, Spezzi A. Lapaquistat acetate: development of a squalene synthase inhibitor for the treatment of hypercholesterolemia.Circulation 123(18), 1974–1985 (2011).
   Google Scholar
• Ladenson PW, Kristensen JD, Ridgway EC et al. Use of the thyroid hormone analogue eprotirome in statin‑treated dyslipidemia.N. Engl. J. Med. 362(10), 906–916 (2010).
   Google Scholar
• Viennois E, Mouzat K, Dufour J, Morel L, Lobaccaro JM, Baron S. Selective liver X receptor modulators (SLiMs): what use in human health? Mol. Cell. Endocrinol. 351(2), 129–141 (2012).
   Google Scholar
• Viennois E, Pommier AJ, Mouzat K et al. Targeting liver X receptors in human health: deadlock or promising trail? Expert Opin. Ther. Targets 15(2), 219–232 (2011).
   Google Scholar
• Chang TY, Li BL, Chang CC, Urano Y. Acyl‑coenzyme A: cholesterol acyltransferases.Am. J. Physiol. Endocrinol. Metab. 297(1), E1–E9 (2009).
   Google Scholar
• Nissen SE, Tuzcu EM, Brewer HB et al. Effect of ACAT inhibition on the progression of coronary atherosclerosis. N. Engl. J. Med. 354(12), 1253–1263 (2006).
   Google Scholar
• Meuwese MC, de Groot E, Duivenvoorden R et al. ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial. JAMA 301(11), 1131–1139 (2009).
   Google Scholar
• Yadav R, France M, Younis N et al. Extended‑release niacin with laropiprant: a review on efficacy, clinical effectiveness and safety. Expert Opin. Pharmacother. 13(9), 1345–1362 (2012).
   Google Scholar
• Boden WE, Probstfield JL, Anderson T et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 365(24), 2255–2267 (2011).
   Google Scholar
• HPS2‑THRIVE randomized placebocontrolled trial in 25 673 high‑risk patients of ER niacin/laropiprant: trial design, prespecified muscle and liver outcomes, and reasons for stopping study treatment. Eur. Heart J. 34(17), 1279–1291 (2013).
   Google Scholar
• Fitzgerald K, Frank‑Kamenetsky M, Shulga‑Morskaya S et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single‑blind, placebo‑controlled, Phase 1 trial. Lancet doi:10.1016/S0140‑6736(13)61914‑5 (2013) (Epub ahead of print).
   Google Scholar
• Kjolby M, Andersen OM, Breiderhoff T et al. Sort1, encoded by the cardiovascular risk locus 1p13.3, is a regulator of hepatic lipoprotein export. Cell Metab. 12(3), 213–223 (2010).
   Google Scholar
• Dias N, Stein CA. Antisense oligonucleotides: basic concepts and mechanisms. Mol. Cancer Ther. 1(5), 347–355 (2002).
   Google Scholar
• Dias N, Stein CA. Potential roles of antisense oligonucleotides in cancer therapy. The example of Bcl‑2 antisense oligonucleotides.Eur. J. Pharm. Biopharm. 54(3), 263–269 (2002).
   Google Scholar
• Davidson BL, McCray PB Jr. Current prospects for RNA interference‑based therapies. Nat. Rev. Genet. 12(5), 329–340 (2011).
   Google Scholar
• Norata GD, Tibolla G, Catapano AL. Gene silencing approaches for the management of dyslipidaemia. Trends Pharmacol. Sci. 34(4), 198–205 (2013).
   Google Scholar
• Crunkhorn S. Trial watch: PCSK9 antibody reduces LDL cholesterol. Nat. Rev. Drug Discov. 11(1), 11 (2012).
   Google Scholar